Reversible cardiomyopathy after high-dose interleukin-2 therapy.
We observed two patients who developed moderate global myocardial dysfunction during therapy with high-dose interleukin-2 (IL-2). Although cardiac enzymes became markedly elevated at the completion of a full course of IL-2, patients exhibited no ischemic symptoms. Serial echocardiography documented global myocardial dysfunction, which resolved in 5 days in one patient but persisted beyond 4 weeks in another. Asymptomatic reversible myocardial injury can occur with high-dose IL-2 and can persist beyond 4 weeks after stopping therapy. Review of the literature suggests an IL-2-associated myocarditis as an etiology.
Goel
M
M
Department of Internal Medicine, Wayne State University School of Medicine, Harper Hospital, Detroit, Michigan 48201.
Flaherty
L
L
Lavine
S
S
Redman
B G
BG
D000328:Adult; D002292:Carcinoma, Renal Cell / Q000628:therapy; D009202:Cardiomyopathies / Q000097:blood / Q000139:chemically induced* / Q000473:pathology; D003402:Creatine Kinase / Q000097:blood; D004452:Echocardiography; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D007376:Interleukin-2 / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000628:therapy; D008297:Male; D008545:Melanoma / Q000628:therapy; D008875:Middle Aged; D011994:Recombinant Proteins / Q000009:adverse effects; D016277:Ventricular Function, Left
D007155:Immunologic Factors; D007376:Interleukin-2; D011994:Recombinant Proteins; D003402:Creatine Kinase